|
市場調査レポート
商品コード
1738613
間質性膀胱炎治療薬の世界市場規模：タイプ別、販売チャネル別、地域範囲別および予測Global Interstitial Cystitis Drugs Market Size By Type (Oral Therapy, Intravesical Therapy), By Sales Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geographic Scope And Forecast |
||||||
|
|||||||
| 間質性膀胱炎治療薬の世界市場規模：タイプ別、販売チャネル別、地域範囲別および予測 |
|
出版日: 2025年05月12日
発行: Verified Market Research
ページ情報: 英文 202 Pages
納期: 2～3営業日
|
- 全表示
- 概要
- 図表
- 目次
間質性膀胱炎治療薬の市場規模と予測
間質性膀胱炎治療薬市場規模は、2024年には3億5,664万米ドルと評価され、2026～2032年にかけてCAGR 5.00%で成長し、2032年には5億844万米ドルに達すると予測されています。
間質性膀胱炎の有病率の高さが、世界の間質性膀胱炎治療薬市場を牽引しています。遺伝子治療の登場は世界市場にプラスの影響を与えています。さらに、これらの薬剤は高価であり、多くの副作用を引き起こします。そのため、再生療法や遺伝子治療といった革新的な治療法を確立する企業が増えています。こうした治療法は、すでに市場に出回っている従来型適応外薬に比べて副作用が少ないからです。間質性膀胱炎治療薬の世界市場レポートは、市場の全体的な評価を記載しています。主要セグメント、動向、市場促進要因、抑制要因、競合情勢、市場で重要な役割を果たしている要因などを包括的に分析しています。
間質性膀胱炎治療薬の世界市場定義
間質性膀胱炎（IC）は、一般に有痛性膀胱症候群と呼ばれ、膀胱の圧迫感や痛み、腰、骨盤、下腹部の痛みを伴うことが多い慢性の膀胱疾患です。患者は軽度から重度までの痛みを経験する可能性があります。間質性膀胱炎に罹患すると、脳への骨盤神経の信号が混同されます。その結果、尿意切迫感、しばしば少量の尿が観察されます。平均すると、人は1日に7回排尿するが、ICの重症例では1日に40～60回排尿することもあります。ICは感染症ではありませんが、しばしば膀胱炎と間違われます。間質性膀胱炎は膀胱の上皮層の欠損によって引き起こされ、上皮が漏れることで尿中の有害物質が膀胱壁を刺激します。
間質性膀胱炎の治療には、それぞれ経口療法と膀胱内療法が第一選択と第二選択となっています。しかし、すべての患者に有効な治療法はないです。治療方針はそれぞれの患者の症状によって決定されます。症状をなくすために、大多数の患者はさまざまな治療（または治療の組み合わせ）を試みる。現在、間質性膀胱炎の治療として承認されているのは、エルミロンとRIMSO-50（ジメチルスルホキシド）の2種類だけです。これらの薬剤は対症療法よりも有効であることが示されています。しかし、これらの薬の価格は高いです。そのため、多くの患者が病気の症状を和らげるために、主に適応外の薬を服用しています。
間質性膀胱炎治療薬の世界市場概要
間質性膀胱炎の有病率の高さが、世界の間質性膀胱炎治療薬市場を牽引しています。遺伝子治療の登場は世界市場にプラスの影響を与えています。間質性膀胱炎の治療として承認されているものも適応外となっているものも、そのほとんどが低分子化合物であり、病気を完治させることはできず、患者に副作用を及ぼし、しかも高価です。間質性膀胱炎患者は下部尿路障害や膀胱痛などの症状を経験します。女性の罹患率が高いです。アレルギー、線維筋痛症、子宮内膜症など多数の合併症がこの疾患と関連しています。
間質性膀胱炎の症例数の増加が、間質性膀胱炎治療薬の需要を牽引しています。入手可能な間質性膀胱炎治療薬の欠点のため、企業は副作用の少ない再生療法や遺伝子治療などの革新的な治療法を開発しています。このような治療法の開発は需要を牽引すると考えられます。このように、間質性膀胱炎の高い有病率と遺伝子治療の出現が相まって、予測期間中の間質性膀胱炎治療薬市場規模の成長を牽引することになると考えられます。
間質性膀胱炎の主要課題は、利用可能な治療法が数種類あるにもかかわらず、普遍的に受け入れられる治療法がないことです。薬剤のFDA承認が得られていないことが、間質性膀胱炎治療薬の世界市場にとって大きな抑制要因となっています。しかし、間質性膀胱炎治療薬市場は現在、利用可能な製品の有効性とコンプライアンスに関する制限のために弱体化しています。承認された治療選択肢が限られていること、知識が不足していること、疾患修飾性治療に対する需要があることも、さらなる要因です。
目次
第1章 イントロダクション
- 市場の定義
- 市場セグメンテーション
- 調査スケジュール
- 前提条件
- 限界
第2章 調査手法
- データマイニング
- 二次調査
- 一次調査
- 専門家の助言
- クオリティチェック
- 最終レビュー
- データの三角測量
- ボトムアップアプローチ
- トップダウンアプローチ
- 調査の流れ
第3章 エグゼクティブサマリー
- 市場概要
- 地域別間質性膀胱炎治療薬の世界市場分析（CAGR）
- 間質性膀胱炎治療薬の世界市場：タイプ別
- 間質性膀胱炎治療薬の世界市場：流通チャネル別
- 今後の市場機会
- 世界市場内訳
第4章 市場展望
- 市場促進要因
- 米国における間質性膀胱炎の高い有病率
- 研究活動の活発化
- 市場抑制要因
- 消費者の認識不足、限られた医薬品承認、高額治療費
- 市場機会
- 再生療法や遺伝子治療などの革新的治療法の出現
- 間質性膀胱炎治療薬の世界市場におけるCOVID-19の影響
- ポーターのファイブフォース分析
- 製品ライフライン
第5章 タイプ別市場
- 概要
- 経口療法
- 膀胱内療法
第6章 流通チャネル別市場
- 概要
- 病院薬局
- 小売薬局
- オンライン薬局
第7章 地域別市場
- 概要
- 北米
- 米国
- カナダ
- メキシコ
- 欧州
- ドイツ
- フランス
- 英国
- その他の欧州
- アジア太平洋
- 日本
- 中国
- インド
- その他のアジア太平洋
- その他の地域
- 中東・アフリカ
- ラテンアメリカ
第8章 競争情勢
- 概要
- 競合シナリオ
- 企業市場ランキング分析
第9章 企業プロファイル
- PFIZER INC.
- JOHNSON & JOHNSON
- KYORIN PHARMACEUTICAL
- UCB PHARMA
- ASTELLAS PHARMA
- ELI LILLY AND COMPANY
- BAYER AG
- LIPELLA PHARMACEUTICALS
- SEIKAGAKU CORPORATION
- GRUNENTHAL
LIST OF TABLES
- TABLE1 GLOBAL INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
- TABLE 2 GLOBAL INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
- TABLE 3 GLOBAL INTERSTITIAL CYSTITIS DRUGS MARKET, BY GEOGRAPHY, 2021 - 2028 (USD MILLION)
- TABLE 4 NORTH AMERICA INTERSTITIAL CYSTITIS DRUGS MARKET, BY COUNTRY, 2021 - 2028 (USD MILLION)
- TABLE 5 NORTH AMERICA INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
- TABLE 6 NORTH AMERICA INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
- TABLE 7 U.S. INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
- TABLE 8 U.S. INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
- TABLE 9 CANADA INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
- TABLE10 CANADA INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
- TABLE11 MEXICO INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
- TABLE12 MEXICO INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
- TABLE13 EUROPE INTERSTITIAL CYSTITIS DRUGS MARKET, BY COUNTRY, 2021 - 2028 (USD MILLION)
- TABLE14 EUROPE INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
- TABLE15 EUROPE INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
- TABLE16 GERMANY INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
- TABLE17 GERMANY INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
- TABLE18 FRANCE INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
- TABLE19 FRANCE INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
- TABLE 20 U.K. INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
- TABLE 21 U.K. INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
- TABLE 22 REST OF EUROPE INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
- TABLE 23 REST OF EUROPE INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
- TABLE 24 ASIA PACIFIC INTERSTITIAL CYSTITIS DRUGS MARKET, BY COUNTRY, 2021 - 2028 (USD MILLION)
- TABLE 25 ASIA PACIFIC INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
- TABLE 26 ASIA PACIFIC INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
- TABLE 27 JAPAN INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
- TABLE 28 JAPAN INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
- TABLE 29 CHINA INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
- TABLE 30 CHINA INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
- TABLE 31 INDIA INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
- TABLE 32 INDIA INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
- TABLE 33 REST OF ASIA PACIFIC INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
- TABLE 34 REST OF ASIA PACIFIC INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
- TABLE 35 ROW INTERSTITIAL CYSTITIS DRUGS MARKET, BY COUNTRY, 2021 - 2028 (USD MILLION)
- TABLE 36 ROW INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
- TABLE 37 ROW INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
- TABLE 38 MIDDLE EAST AND AFRICA INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
- TABLE 39 MIDDLE EAST AND AFRICA INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
- TABLE 40 LATIN AMERICA INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE, 2021 - 2028 (USD MILLION)
- TABLE 41 LATIN AMERICA INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL, 2021 - 2028 (USD MILLION)
- TABLE 42 COMPANY MARKET RANKING ANALYSIS
- TABLE 43 PFIZER INC.: PRODUCT BENCHMARKING
- TABLE 44 PFIZER INC.: KEY DEVELOPMENT
- TABLE 45 JOHNSON & JOHNSON: PRODUCT BENCHMARKING
- TABLE 46 KYORIN PHARMACEUTICAL: PRODUCT BENCHMARKING
- TABLE 47 KYORIN PHARMACEUTICAL: KEY DEVELOPMENT
- TABLE 48 UCB PHARMA: PRODUCT BENCHMARKING
- TABLE 49 UCB PHARMA: KEY DEVELOPMENT
- TABLE 50 ASTELLAS PHARMA: PRODUCT BENCHMARKING
- TABLE 51 ELI LILLY AND COMPANY: PRODUCT BENCHMARKING
- TABLE 52 ELI LILLY AND COMPANY: KEY DEVELOPMENT
- TABLE 53 BAYER AG: PRODUCT BENCHMARKING
- TABLE 54 BAYER AG: KEY DEVELOPMENT
- TABLE 55 LIPELLA PHARMACEUTICALS: PRODUCT BENCHMARKING
- TABLE 56 SEIKAGAKU CORPORATION: PRODUCT BENCHMARKING
- TABLE 57 SEIKAGAKU CORPORATION: KEY DEVELOPMENT
- TABLE 58 GRUNENTHAL: PRODUCT BENCHMARKING
LIST OF FIGURES
- FIGURE1 GLOBAL INTERSTITIAL CYSTITIS DRUGS MARKET SEGMENTATION
- FIGURE 2 RESEARCH TIMELINES
- FIGURE 3 DATA TRIANGULATION
- FIGURE 4 MARKET RESEARCH FLOW
- FIGURE 5 GLOBAL INTERSTITIAL CYSTITIS DRUGS MARKET OVERVIEW
- FIGURE 6 GLOBAL INTERSTITIAL CYSTITIS DRUGS MARKET GEOGRAPHICAL ANALYSIS, 2021-2028
- FIGURE 7 GLOBAL INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE USD MILLION)
- FIGURE 8 GLOBAL INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL (USD MILLION)
- FIGURE 9 FUTURE MARKET OPPORTUNITIES
- FIGURE10 NORTH AMERICA DOMINATED THE MARKET IN 2020
- FIGURE11 MARKET OVERVIEW
- FIGURE12 PORTER'S FIVE FORCES ANALYSIS: GLOBAL INTERSTITIAL CYSTITIS DRUGS MARKET
- FIGURE13 PRODUCT LIFELINE: GLOBAL INTERSTITIAL CYSTITIS DRUGS MARKET
- FIGURE14 GLOBAL INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE
- FIGURE15 GLOBAL INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL
- FIGURE16 COMPOUND ANNUAL GROWTH RATE OF MARKET IN PROMINENT COUNTRIES ACROSS THE GLOBE
- FIGURE17 NORTH AMERICA MARKET SNAPSHOT
- FIGURE18 THE U.S. MARKET SNAPSHOT
- FIGURE19 CANADA MARKET SNAPSHOT
- FIGURE 20 MEXICO MARKET SNAPSHOT
- FIGURE 21 EUROPE MARKET SNAPSHOT
- FIGURE 22 GERMANY MARKET SNAPSHOT
- FIGURE 23 FRANCE MARKET SNAPSHOT
- FIGURE 24 U.K. MARKET SNAPSHOT
- FIGURE 25 ASIA PACIFIC MARKET SNAPSHOT
- FIGURE 26 JAPAN MARKET SNAPSHOT
- FIGURE 27 CHINA MARKET SNAPSHOT
- FIGURE 28 INDIA MARKET SNAPSHOT
- FIGURE 29 ROW SNAPSHOT
- FIGURE 30 MIDDLE EAST AND AFRICA MARKET SNAPSHOT
- FIGURE 31 LATIN AMERICA MARKET SNAPSHOT
- FIGURE 32 KEY STRATEGIC DEVELOPMENTS
- FIGURE 33 PFIZER INC.: COMPANY INSIGHT
- FIGURE 34 PFIZER INC.: SWOT ANALYSIS
- FIGURE 35 JOHNSON & JOHNSON: COMPANY INSIGHT
- FIGURE 36 JOHNSON & JOHNSON: BREAKDOWN
- FIGURE 37 JOHNSON & JOHNSON: SWOT ANALYSIS
- FIGURE 38 KYORIN PHARMACEUTICAL: COMPANY INSIGHT
- FIGURE 39 KYORIN PHARMACEUTICAL: BREAKDOWN
- FIGURE 40 KYORIN PHARMACEUTICAL: SWOT ANALYSIS
- FIGURE 41 UCB PHARMA: COMPANY INSIGHT
- FIGURE 42 UCB PHARMA: BREAKDOWN
- FIGURE 43 UCB PHARMA: SWOT ANALYSIS
- FIGURE 44 ASTELLAS PHARMA: COMPANY INSIGHT
- FIGURE 45 ASTELLAS PHARMA: BREAKDOWN
- FIGURE 46 ASTELLAS PHARMA: SWOT ANALYSIS
- FIGURE 47 ELI LILLY AND COMPANY: COMPANY INSIGHT
- FIGURE 48 ELI LILLY AND COMPANY: BREAKDOWN
- FIGURE 49 BAYER AG: COMPANY INSIGHT
- FIGURE 50 BAYER AG: BREAKDOWN
- FIGURE 51 LIPELLA PHARMACEUTICALS: COMPANY INSIGHT
- FIGURE 52 SEIKAGAKU CORPORATION: COMPANY INSIGHT
- FIGURE 53 SEIKAGAKU CORPORATION: BREAKDOWN
- FIGURE 54 GRUNENTHAL: COMPANY INSIGHT
Interstitial Cystitis Drugs Market Size And Forecast
Interstitial Cystitis Drugs Market size was valued at USD 356.64 Million in 2024 and is projected to reach USD 508.44 Million by 2032, growing at a CAGR of 5.00% from 2026 to 2032.
The high prevalence of interstitial cystitis is driving the global Interstitial Cystitis Drugs Market. The advent of gene therapy is positively impacting the global market. Moreover, these drugs are expensive and cause many side effects. This is encouraging companies to establish innovative treatment options such as regenerative therapy and gene therapy as these drugs cause lesser side effects compared to the conventional off-label drugs already available in the market. The Global Interstitial Cystitis Drugs Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.
Global Interstitial Cystitis Drugs Market Definition
Interstitial cystitis (IC), commonly referred to as painful bladder syndrome, is a chronic bladder issue often associated with bladder pressure and pain, as well as occasional pain in the lower back, pelvis, or lower abdomen. The patient could experience pain ranging from mild to severe. The pelvic nerve signal to the brain gets mixed up in an individual suffering from interstitial cystitis. Consequently, an urgency to urinate, often in a small volume, is observed. On average, a person urinates seven times a day; however, in severe cases of IC, urination may occur around 40-60 times a day. IC is not an infection but is often mistaken to be a bladder infection. Interstitial cystitis is caused by a defect of the epithelium layer of the bladder, leaking epithelium allows toxic substances in urine to irritate the bladder wall.
Oral therapy and intravesical therapy are the first- and second-line choices for treating interstitial cystitis, respectively. However, no one treatment is effective for all patients. The course of treatment is determined by each patient's symptoms. To eliminate the symptoms, the majority of patients try various treatments (or treatment combinations). There are currently just two approved drugs for treating interstitial cystitis, ELMIRON, and RIMSO-50 (dimethyl sulfoxide). These drugs have been shown to be more effective than symptomatic treatments. But the price of these drugs is high. Therefore, a lot of patients take off-label drugs largely to relieve the symptoms of the disease.
Global Interstitial Cystitis Drugs Market Overview
The high prevalence of interstitial cystitis is driving the global Interstitial Cystitis Drugs Market. The advent of gene therapy is positively impacting the global market. Most of the approved and off-label drugs for interstitial cystitis are small molecules, which cannot completely cure the disease, have side effects on the patients, and are expensive. Patients suffering from interstitial cystitis experience symptoms such as lower urinary tract issues and bladder pain. Women are highly affected by this condition. Numerous comorbidities, including allergies, fibromyalgia, and endometriosis, are linked to this condition.
The increasing number of interstitial cystitis cases is driving the demand for interstitial cystitis drugs. Owing to the disadvantages of available drugs for interstitial cystitis, companies are developing innovative treatment options such as regenerative therapy and gene therapy that have fewer side effects. The development of such therapies will drive demand. Thus, the high prevalence of interstitial cystitis coupled with the advent of gene therapy will drive the Interstitial Cystitis Drugs Market size growth during the forecast period.
The major challenge for Interstitial Cystitis is that though there are several types of treatment available, no one treatment is universally acceptable. The lack of FDA approval for drugs is a major restraining factor for the Global Interstitial Cystitis Drugs Market. However, the Interstitial Cystitis Drugs Market is currently weak owing to limitations regarding the efficacy and compliance of available products. Limited approved treatment options, a lack of knowledge, and the demand for disease-modifying treatments are additional factors.
Global Interstitial Cystitis Drugs Market Segmentation Analysis
The Global Interstitial Cystitis Drugs Market is segmented on the basis of Type, Sales Channel, and Geography.
Interstitial Cystitis Drugs Market, By Type
- Oral Therapy
- Intravesical Therapy
Based on Type, the market is bifurcated into Oral Therapy, and Intravesical Therapy. Oral Therapy accounted for the largest market share of 56.96% in 2020, with a market value of USD 674.05 Million, and is projected to grow at a CAGR of 4.44% during the forecast period. Intravesical Therapy was the second-largest market in 2020, valued at USD 509.25 Million in 2020.
Interstitial Cystitis Drugs Market, By Sales Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Based on the Sales Channel, the market is bifurcated into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Hospital Pharmacies accounted for the largest market share of 67.69% in 2020, with a market value of USD 800.99 Million, and is projected to grow at a CAGR of 4.52% during the forecast period. Retail Pharmacies were the second-largest market in 2020, valued at USD 309.48 Million in 2020.
Interstitial Cystitis Drugs Market, By Geography
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Key Players
The "Global Interstitial Cystitis Drugs Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Pfizer, Johnson & Johnson, Kyorin Pharmaceutical, UCB Pharma, Astellas Pharma, Bayer, Eli Lilly, Lipella Pharmaceuticals, Seikagaku Corporation, and Grunenthal. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.
Key Developments
- In January 2021, The Ministry of Health, Labour and Welfare (hereinafter "MHLW") had given Kyorin Pharmaceutical Co., Ltd. permission to market interstitial cystitis "Zymso(R) Intravesical Solution 50%" (hereinafter "Zymso") in Japan. Kyorin Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of KYORIN Holdings, Inc.
- In April 2021: Kyorin Pharmaceutical Co., Ltd. a wholly owned subsidiary of KYORIN Holdings, Inc., launched Interstitial cystitis "Zymso(R) Intravesical Solution 50%" (hereinafter "Zymso").
- Ace Matrix Analysis
- The Ace Matrix provided in the report would help to understand how the major key players involved in this industry are performing as we provide a ranking for these companies based on various factors such as service features & innovations, scalability, innovation of services, industry coverage, industry reach, and growth roadmap. Based on these factors, we rank the companies into four categories as Active, Cutting Edge, Emerging, and Innovators.
- Market Attractiveness
- The image of market attractiveness provided would further help to get information about the region that is majorly leading in the Global Interstitial Cystitis Drugs Market. We cover the major impacting factors that are responsible for driving the industry growth in the given region.
- Porter's Five Forces
- The image provided would further help to get information about Porter's five forces framework providing a blueprint for understanding the behavior of competitors and a player's strategic positioning in the respective industry. Porter's five forces model can be used to assess the competitive landscape in Global Interstitial Cystitis Drugs Market, gauge the attractiveness of a certain sector, and assess investment possibilities.
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 MARKET DEFINITION
- 1.2 MARKET SEGMENTATION
- 1.3 RESEARCH TIMELINES
- 1.4 ASSUMPTIONS
- 1.5 LIMITATIONS
2 RESEARCH METHODOLOGY
- 2.1 DATA MINING
- 2.2 SECONDARY RESEARCH
- 2.3 PRIMARY RESEARCH
- 2.4 SUBJECT MATTER EXPERT ADVICE
- 2.5 QUALITY CHECK
- 2.6 FINAL REVIEW
- 2.7 DATA TRIANGULATION
- 2.8 BOTTOM-UP APPROACH
- 2.9 TOP-DOWN APPROACH
- 2.10 RESEARCH FLOW
3 EXECUTIVE SUMMARY
- 3.1 MARKET OVERVIEW
- 3.2 GLOBAL INTERSTITIAL CYSTITIS DRUGS MARKET GEOGRAPHICAL ANALYSIS (CAGR %)
- 3.3 GLOBAL INTERSTITIAL CYSTITIS DRUGS MARKET, BY TYPE (USD MILLION)
- 3.4 GLOBAL INTERSTITIAL CYSTITIS DRUGS MARKET, BY SALES CHANNEL (USD MILLION)
- 3.5 FUTURE MARKET OPPORTUNITIES
- 3.6 GLOBAL MARKET SPLIT
4 MARKET OUTLOOK
- 4.1 MARKET DRIVERS
- 4.1.1 HIGH PREVALENCE OF INTERSTITIAL CYSTITIS IN THE US
- 4.1.2 RESEARCH ACTIVITY ON A RISE
- 4.2 MARKET RESTRAINTS
- 4.2.1 LACK OF AWARENESS AMONG CONSUMERS, LIMITED DRUG APPROVAL, AND HIGH-COST TREATMENT
- 4.3 MARKET OPPORTUNITIES
- 4.3.1 EMERGENCE OF INNOVATIVE TREATMENT OPTIONS SUCH AS REGENERATIVE THERAPY AND GENE THERAPY
- 4.4 IMPACT OF COVID -19 ON GLOBAL INTERSTITIAL CYSTITIS DRUGS MARKET
- 4.1 PORTER'S FIVE FORCES ANALYSIS
- 4.2 PRODUCT LIFELINE
5 MARKET, BY TYPE
- 5.1 OVERVIEW
- 5.2 ORAL THERAPY
- 5.3 INTRAVESICAL THERAPY
6 MARKET, BY SALES CHANNEL
- 6.1 OVERVIEW
- 6.2 HOSPITAL PHARMACIES
- 6.3 RETAIL PHARMACIES USES
- 6.4 ONLINE PHARMACIES
7 MARKET, BY GEOGRAPHY
- 7.1 OVERVIEW
- 7.2 NORTH AMERICA
- 7.2.1 THE U.S.
- 7.2.2 CANADA
- 7.2.3 MEXICO
- 7.3 EUROPE
- 7.3.1 GERMANY
- 7.3.2 FRANCE
- 7.3.3 U.K.
- 7.3.4 REST OF EUROPE
- 7.4 ASIA PACIFIC
- 7.4.1 JAPAN
- 7.4.2 CHINA
- 7.4.3 INDIA
- 7.4.4 REST OF ASIA PACIFIC
- 7.5 ROW
- 7.5.1 MIDDLE EAST AND AFRICA
- 7.5.2 LATIN AMERICA
8 COMPETITIVE LANDSCAPE
- 8.1 OVERVIEW
- 8.2 COMPETITIVE SCENARIO
- 8.3 COMPANY MARKET RANKING ANALYSIS
9 COMPANY PROFILES
- 9.1 PFIZER INC.
- 9.1.1 COMPANY OVERVIEW
- 9.1.2 COMPANY INSIGHTS
- 9.1.3 PRODUCT BENCHMARKING
- 9.1.4 KEY DEVELOPMENT
- 9.1.5 SWOT ANALYSIS
- 9.2 JOHNSON & JOHNSON
- 9.2.1 COMPANY OVERVIEW
- 9.2.2 COMPANY INSIGHTS
- 9.2.3 SEGMENT BREAKDOWN
- 9.2.4 PRODUCT BENCHMARKING
- 9.2.5 SWOT ANALYSIS
- 9.3 KYORIN PHARMACEUTICAL
- 9.3.1 COMPANY OVERVIEW
- 9.3.2 COMPANY INSIGHTS
- 9.3.3 SEGMENT BREAKDOWN
- 9.3.4 PRODUCT BENCHMARKING
- 9.3.5 KEY DEVELOPMENT
- 9.3.6 SWOT ANALYSIS
- 9.4 UCB PHARMA
- 9.4.1 COMPANY OVERVIEW
- 9.4.2 COMPANY INSIGHTS
- 9.4.3 SEGMENT BREAKDOWN
- 9.4.4 PRODUCT BENCHMARKING
- 9.4.5 KEY DEVELOPMENT
- 9.4.6 SWOT ANALYSIS
- 9.5 ASTELLAS PHARMA
- 9.5.1 COMPANY OVERVIEW
- 9.5.2 COMPANY INSIGHTS
- 9.5.3 SEGMENT BREAKDOWN
- 9.5.4 PRODUCT BENCHMARKING
- 9.5.5 SWOT ANALYSIS
- 9.6 ELI LILLY AND COMPANY
- 9.6.1 COMPANY OVERVIEW
- 9.6.2 COMPANY INSIGHTS
- 9.6.3 SEGMENT BREAKDOWN
- 9.6.4 PRODUCT BENCHMARKING
- 9.6.5 KEY DEVELOPMENT
- 9.7 BAYER AG
- 9.7.1 COMPANY OVERVIEW
- 9.7.2 COMPANY INSIGHTS
- 9.7.3 SEGMENT BREAKDOWN
- 9.7.4 PRODUCT BENCHMARKING
- 9.7.5 KEY DEVELOPMENT
- 9.8 LIPELLA PHARMACEUTICALS
- 9.8.1 COMPANY OVERVIEW
- 9.8.2 COMPANY INSIGHTS
- 9.8.3 PRODUCT BENCHMARKING
- 9.9 SEIKAGAKU CORPORATION
- 9.9.1 COMPANY OVERVIEW
- 9.9.2 COMPANY INSIGHTS
- 9.9.3 SEGMENT BREAKDOWN
- 9.9.4 PRODUCT BENCHMARKING
- 9.9.5 KEY DEVELOPMENT
- 9.10 GRUNENTHAL
- 9.10.1 COMPANY OVERVIEW
- 9.10.2 COMPANY INSIGHTS
- 9.10.3 PRODUCT BENCHMARKING
